Legionnaires’ Bacteria at GSK

GlaxoSmithKline temporarily shuts down a manufacturing plant in North Carolina after Legionella bacteria are detected in two external cooling towers.

Written byJef Akst
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Colorized scanning electron micrograph of Legionella pneumophila bacteriaWIKIMEDIA, CDCOn Tuesday (August 11), pharmaceutical giant GlaxoSmithKline (GSK) closed down a manufacturing plant in Zebulon, North Carolina, and sent employees home after the bacteria that cause Legionnaires’ disease were discovered in a cooling tower. The pathogen was subsequently found in a second cooling tower. But after concluding that the contamination posed no risk to its employees or products, the pharma company announced it would reopen by the weekend, after both towers have been cleaned.

“Given the location and level of bacteria found, this situation posed no risk to the products manufactured inside the building,” a GSK spokesperson told The Wall Street Journal yesterday (August 13). “We anticipate resuming production in the next 72 hours after cleaning, disinfecting, and returning the plant back to normal operating conditions.”

Separately, company spokesperson Jenni Ligday told FiercePharma that all drugs produced in the facility before the contamination was discovered are fine to use. “The cooling towers are external units with no contact with product or employees. Our products are safe and effective when used as prescribed.”

This marks the second widely reported discovery of Legionella in cooling towers this year. Since July, New York City health authorities have identified the bacterium in five ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies